A similar regimen has been historically used as first-line therapy in systemic-onset JIA (soJIA), recently renamed Still’s disease (comprising both soJIA and the adult-onset Still’s disease), although this should not delay early initiation of biologic therapy with interleukin (IL)-1 or IL-6 blockade as first-line therapy, which results in better outcomes [17]. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.